← Leaderboards
Maria Adelaida Gomez
Univ Of Maryland, College Park
$2,476,800
Attributed
$3,393,468
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $622.5K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,393,468 · 3
By mechanism
R01$2,506,913 · 2
U19$886,555 · 1
Top collaborators
- Najib M. El-Sayed3 shared
Most similar at Univ Of Maryland, College Park
Same institution · by research overlap
- Najib M. El-Sayed$13,231,528
- Megan Lindsay Fritz$1,969,281
- Olga Lucia Fernandez$96,867
Others in their field
Top investigators on “Parasites”
- Stephen Lev Hoffman · Sanaria, Inc.$58,168,134
- L David Sibley · Washington University$47,818,729
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Wilhelmus G. J. Hol · University Of Washington$32,390,237
- Philip Jon Rosenthal · University Of California San Francisco$31,794,731
- Daniel F. Hoft · Saint Louis University$31,137,771
Research focus
ParasitesTreatment FailureImmune ResponseCutaneous LeishmaniasisMacrophageVianniaCellsBiological MarkersResponseMolecular ProfilingPredispositionBaseLeishmaniasisTreatment ResponseTreatment OutcomeVaccinesReportingPathogenPharmaceutical PreparationsColombiaValidationMonocyteMetabolicMolecular
Grant awards (13)
Host and parasite determinants of Leishmania Viannia persistence in naturally infected human populations$595,744
R01 · FY2025 · AI
Host and parasite determinants of Leishmania Viannia persistence in naturally infected human populations$615,131
R01 · FY2024 · AI
Host and parasite determinants of Leishmania Viannia persistence in naturally infected human populations$622,462
R01 · FY2023 · AI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$210,955
U19 · FY2021 · AI · contact PI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$167,031
U19 · FY2020 · AI · contact PI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$161,918
U19 · FY2019 · AI · contact PI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$188,573
U19 · FY2018 · AI · contact PI
The Innate Immune Response As A Therapeutic Target For Cutaneous Leishmaniasis$158,078
U19 · FY2017 · AI · contact PI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,340
R01 · FY2017 · AI · contact PI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,699
R01 · FY2016 · AI · contact PI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,828
R01 · FY2015 · AI · contact PI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,877
R01 · FY2014 · AI · contact PI
Macrophage drug transport and metabolism in the outcome of antileishmania therapy$134,832
R01 · FY2013 · AI · contact PI